Binimetinib - Array BioPharma/Pierre Fabre

Drug Profile

Binimetinib - Array BioPharma/Pierre Fabre

Alternative Names: ARRY-162; ARRY-438162; Balimek; MEK-162; ONO-7703

Latest Information Update: 29 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Array BioPharma; Dana-Farber Cancer Institute
  • Developer Array BioPharma; Dana-Farber Cancer Institute; German Cancer Research Center; Mayo Clinic; Memorial Sloan-Kettering Cancer Center; Merck KGaA; National Cancer Institute (USA); Novartis; Pierre Fabre; Plexxikon; Seoul National University Hospital; University Health Network; University of Heidelberg; University of Pittsburgh
  • Class Amides; Anti-inflammatories; Antineoplastics; Benzimidazoles; Fluorine compounds; Small molecules
  • Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Malignant melanoma
  • Phase III Colorectal cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase II Haematological malignancies; Multiple myeloma; Neurofibromatoses; Non-small cell lung cancer; Solid tumours
  • Phase I/II Acute myeloid leukaemia; Biliary cancer; Breast cancer; Chronic myeloid leukaemia; Gastrointestinal stromal tumours; Pancreatic cancer
  • Discontinued Rheumatoid arthritis; Uveal melanoma

Most Recent Events

  • 23 Mar 2018 University of Colorado plans a phase II trial for Colorectal cancer (Combination therapy, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA (PO), in May 2018 (NCT03475004)
  • 21 Feb 2018 Ono pharmaceutical a phase I/II trial for Solid tumours (Late-stage disease) in Japan , (JapicCTI-183874)
  • 20 Feb 2018 Novartis completes a phase Ib/II trial in Malignant melanoma (Combination therapy) in USA, Australia, Germany, Italy, Norway and Netherlands (PO) (NCT01781572)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top